Abivax SA (ABVX) vs Corcept Therapeutics (CORT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Corcept Therapeutics (CORT) has outperformed Abivax SA (ABVX) over the past year, losing 17.7% versus a loss of 38.5%. Corcept Therapeutics is the larger company by market cap ($6.96 billion vs $6.41 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | CORT |
|---|---|---|
| Share price | $73.20 | $63.62 |
| Market cap | $6.41B | $6.96B |
| 1-day change | -9.24% | -2.09% |
| YTD return | -45.72% | +82.82% |
| 1-year return | -38.55% | -17.69% |
| 5-year return | — | +196.04% |
| P/E ratio (TTM) | — | 47.83 |
| Forward P/E | — | 12.77 |
| EPS (TTM) | $-6.08 | $1.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $761.41M |
| Revenue growth (YoY) | — | +12.79% |
| Net income (latest FY) | — | $99.65M |
| Gross margin | — | 98.30% |
| Operating margin | — | 5.88% |
| Net margin | — | 13.09% |
| 52-week high | $148.83 | $126.38 |
| 52-week low | $62.70 | $28.66 |
| Distance from 52-week high | -50.82% | -49.66% |
| Analyst consensus | none | buy |
| Avg. price target upside | +123.47% | +124.14% |
| Average volume | 1.35M | 1.26M |
| Shares outstanding | 87.54M | 109.44M |
| Employees | 98 | 730 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CORT has outperformed ABVX by 20.9 percentage points over the past year.
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
ABVX vs CORT FAQ
Which is bigger, Abivax SA or Corcept Therapeutics?
Corcept Therapeutics (CORT) is larger, with a market capitalization of $6.96B compared with $6.41B for Abivax SA (ABVX).
Which stock has performed better over the past year, ABVX or CORT?
CORT returned -17.69% over the past 12 months, compared with -38.55% for ABVX (price return, excluding dividends). Past performance does not predict future results.
Are Abivax SA and Corcept Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.